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Abstract
Background: The best surgical modality for treating chronic periprosthetic hip infections remains controversial,
with a lack of randomised controlled studies. The aim of this systematic review is to compare the infection
recurrence rate after a single-stage versus a two-stage exchange arthroplasty, and the rate of cemented versus
cementless single-stage exchange arthroplasty for chronic periprosthetic hip infections.
Methods: We searched for eligible studies published up to December 2015. Full text or abstract in English were
reviewed. We included studies reporting the infection recurrence rate as the outcome of interest following single-
or two-stage exchange arthroplasty, or both, with a minimum follow-up of 12 months. Two reviewers independently
abstracted data and appraised quality assessment.
Results: After study selection, 90 observational studies were included. The majority of studies were focused on a two-
stage hip exchange arthroplasty (65 %), 18 % on a single-stage exchange, and only a 17 % were comparative studies.
There was no statistically significant difference between a single-stage versus a two-stage exchange in terms of
recurrence of infection in controlled studies (pooled odds ratio of 1.37 [95 % CI = 0.68-2.74, I2 = 45.5 %]).
Similarly, the recurrence infection rate in cementless versus cemented single-stage hip exchanges failed to
demonstrate a significant difference, due to the substantial heterogeneity among the studies.
Conclusion: Despite the methodological limitations and the heterogeneity between single cohorts studies, if we
considered only the available controlled studies no superiority was demonstrated between a single- and two-
stage exchange at a minimum of 12 months follow-up. The overalapping of confidence intervals related to
single-stage cementless and cemented hip exchanges, showed no superiority of either technique.
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Background
There remains an ongoing discrepancy in the literature
between the infection recurrence rates after a single-stage
exchange arthroplasty compared to a two-stage exchange
for chronic periprosthetic hip infections. Infection has
been reported as the third reason for revision after total
hip arthroplasty in the USA [1], complicating 0.5 to 2 % of
primary arthroplasties [2–4].
The operative approach is determined by a combination
of surgeon, patient, joint, and infection factors. Literature
regarding the optimal inclusion and exclusion criteria for
each modality is varied, but there is a general consensus
that a two-stage exchange should be undertaken in
patients with unknown pathogens or those of high-
virulence [5–7].
Previous attempts at addressing this issue have been
undertaken by various prospective [8–10] and retro-
spective cohort studies [11–13] comparing the modal-
ities used, or systematic reviews [14, 15], but due to
various limitations, such as determining the ‘ideal candi-
date’ for each treatment, a definitive conclusion has not
been shown.
In the lack of large prospective, randomised controlled
comparative trials, this comprehensive systematic review
and meta-analysis of observational studies was undertaken
to investigate the relative efficacy, in terms of recurrence
of the infection, in a single- compared to two-stage
exchange arthroplasty for chronic periprosthetic hip infec-
tion. A similar review has been recently reported for peri-
prosthetic knee and shoulder infections [16, 17]. In
addition, we aim to further analyse the infection rates after
cemented and cementless single-stage exchanges, which
have not been previously undertaken.
Methods
Search startegy
We searched for studies published up to December 2015
on the following databases: EMBASE; PubMed/Medline;
Medline Daily Update; Medline In-Process and other non-
indexed citations; Google Scholar; SCOPUS; CINAHL;
Cochrane Central Register of Controlled Trials and
Cochrane Database of Systematic Reviews; NHS Health
Technology Assessment; http://www.google.com; and
http://www.yahoo.com. The search was executed using
MeSH and text keywords [see Appendix 1] and adapted
for each database in order to achieve more sensitivity.
Original study reports as well as review articles were re-
trieved, and the reference lists from all reviewed articles
were assessed to complete the literature search. No
language restrictions were applied.
Eligibility criteria
We included studies that fuflilled the following inclusion
criteria: (a) sample of at least 4 patients with prosthetic
hip infection that underwent a surgical revision; (b)
single-stage or two-stage exchange arthroplasty as surgi-
cal treatment; (c) a minimum follow-up of 12 months;
(d) study reporting results relating to delayed or chronic
infection (6 weeks or later) stages of disease; (e) recur-
rent infection after treatment as outcome; (f ) study de-
sign classifiable as comparative study, prospective or
retrospective study with no compared group.
Study selection
Two investigators independently searched and reviewed
the literature and classified the references in terms of
whether they should be included on the basis of the title
and abstract. In order to include all studies, if full text
was not avaiable, abstracts with enough information to
be qualitative and quantitative assessed were included. If
more than one paper by the same author(s) was re-
trieved and their follow-ups were found to overlap, only
the most recent reference with the longest follow-up
and largest patient series was included. Discrepancies
were solved by consusus.
Data extraction
Data collection was performed by four reviewers. The
following data were extracted: name of author, year of
publication, type of study design, minimum, maximum
and mean period of follow up, number of patients in-
cluded and number of recurrent infections (in case of
comparative studies number of patients per group).
Outcome
Our primary outcome was the recurrent infection rate.
We chose to extract data only of patients who com-
pleted the single-stage or the two-stage revision. We did
not include patients that had received a supplemental
revision for a new infection following the prior septic re-
vision, nor those who did not receive the complete reim-
plantation process, or died for cause unrelated to
infection recurrence.
Quality assessment
In order to reflect the information expected to be
present in each included study, as a measure of quality
we selected and evaluated the following two bias: (1)
retrospective or prospective analysis and source of data
(record bias); (2) relevance and definition of measured
outcome for infection (reporting bias). Two independent
reviewers performed the quality assessment; disagree-
ments were resolved by consensus.
Statistical analysis
Infection recurrence rates were treated as dichotomous
variables using the odds ratio (OR) for meta-analysis of
controlled studies (single-stage versus two-stage) and
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the ratio between number of infection and total number
of patients for proportional meta-analysis of cohort
studies reporting only one treatment group, along with
95 % confidential intervals (CI).
The analysis was performed using extracted patient
data from the individual studies. Because of the differ-
ences among the included studies and several uncon-
trolled variables, we used a random-effect model [18].
The results from individual trials were combined when
possible, but otherwise single forest plots will be re-
ported without the overall duration of follow-up.
In single forest plot, each horizontal line on the graph
represents a case series included in the meta-analysis. The
estimated effect is marked with a solid black square, and
the size of the square represents the weight of the corre-
sponding study plotted in the meta-analysis. The com-
bined total estimate is marked with an unfilled diamond
at the bottom of the forest plot. Statistical heterogeneity
was assessed using the I2 statistic and assume influential
when the I2 was greater than 50 % and p < 0.05 as statisti-
cally significant for the calculation of heterogeneity; I2 il-
lustrates the percentage of the variability in effect
estimates resulting from clinical and/or methodological
heterogeneity rather than sampling error [19, 20].
Forest plots were presented for the following interven-
tions: single-stage, two-stage, single-stage cemented, and
single-stage cementless hip arthroplasties. The presence of
an overlap of the confidence intervals from the two inter-
ventions, for example between single-stage and two stage
exchanges, suggests similar effect of the interventions on
the outcome. Alternatively, non-overlapping CIs suggest
different effects from the interventions studied [21].
We used the following software: StatsDirect [StatsDirect
Ltd, Cheshire, UK] for the proportional meta-analyses and
Review Manager [RevMan version 5.2, The Cochrane
Collaboration, The Nordic Cochrane Centre, Copenhagen
2012] for meta-analyses in controlled studies.
Results
Selection and characteristics of studies
The results of the study selection are shown in Fig. 1.
We found 90 original observational studies. Sixteen
studies reported the results only after a single-stage ex-
change, 59 reported only a two-stage hip exchange and
15 reported the comparison of a single-stage versus a
two-stage. Overall, 31 original studies reported data
about single-stage hip exchange arthroplasty (number of
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Fig. 1 Flow diagram of study selection process
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Table 1 General characteristics, record bias and reporting bias of included studies




Follow Up (months) Design Record
Bias
Reporting Bias (Outcome Measure)
Min Max Mean
Babiak [28] 2012 9 Two 36 180 84 NA Yes NA
Babis [29] 2015 31 Two 20 48 30 Retrospective Yes Symptoms, Imaging, Laboratory
Berend [30] 2013 186 Two 24 180 53 Retrospective NR Culture
Biring [31] 2009 48 Two 120 180 144 Retrospective Yes Culture
Bori [32] 2014 24 Single 25 94 45 Retrospective Yes Culture
Buchholz [33] 1981 583 Single 24 132 – Prospective Yes Culture
Buttaro [34] 2005 29 Two 24 60 32.4 Retrospective Yes Symptoms, Imaging, Laboratory
Cabrita [8] 2007 38 Two 24 102 48 Prospective Yes Culture
Callaghan [35] 1999 12 Single 12 168 109.2 Retrospective Yes Imaging
Camurcu [36] 2015 41 Two 24 96 54 Retrospective Yes Culture
Carlsson [37] 1985 72 Both 12 72 – Prospective Yes Symptoms, Imaging, Culture
Chen [38] 2015 155 Two 36 180 116.4 Retrospective NR Culture
Choi [12] 2013 61 Both 12 132 61 Retrospective Yes Culture
Colyer [10] 1994 37 Two 12 88 36 Unclear Yes Culture
Cordero-Ampuero [39] 2009 36 Two 12 144 52.8 Prospective Yes Culture
D'Angelo [40] 2011 28 Two 18 106 53 Retrospective Yes Symptoms, Imaging, Laboratory
Darley [41] 2009 19 Two 24 36 26 Prospective Yes Symptoms, Culture
De Man [42] 2011 72 Both 17 204 60 Retrospective Yes Culture
Degen [43] 2012 30 Two 24 70 43 Retrospective Yes Symptoms, Culture
Ekpo [44] 2014 19 Two 24 132 48 Retrospective Yes Laboratory, Culture
Evans [45] 2004 23 Two 24 108 48 Prospective NR Symptoms, Culture
Fehring [46] 1999 25 Two 24 98 41 Prospective Yes Symptoms, Laboratory
Fink [47] 2009 36 Two 24 60 35 Prospective Yes Culture
Fitzgerald [48] 1985 131 Two 24 108 49 Retrospective Yes Symptoms
Gao [49] 2008 15 Both 12 37 19 NA NA Culture
Garvin [50] 1994 40 Both 24 120 60 NA NA Culture
Haddad [51] 2000 50 Two 24 104 69.6 Retrospective Yes Symptoms
Hofmann [52] 2005 27 Two 28 148 76 Retrospective Yes Symptoms, Imaging, Laboratory
Hope [53] 1989 80 Both 2 121 – Retrospective Yes Culture
Hsieh [55] 2004 128 Two 24 96 58.8 Retrospective Yes Symptoms, Laboratory
Hsieh [11] 2009 99 Two 24 60 43 Retrospective Yes Symptoms, Culture
Hsieh [54] 2013 28 Two 48 120 86 Retrospective Yes Symptoms,Culture, Laboratory
Hughes [24] 1979 26 Both 32 83 51 Retrospective Yes Symptoms, Imaging, Laboratory, Culture
Ibrahim [56] 2014 125 Two 60 75 103.2 Retrospective Yes Symptoms, Laboratory, Culture
Ilchmann [57] 2015 38 Single 24 181.2 79.2 Retrospective Yes Symptoms, Culture
Jenny [58] 2014 63 Single 36 72 – Retrospective Yes Symptoms, Culture
Johnson [59] 2013 66 Two 24 105 45 Retrospective Yes Symptoms, Laboratory, Culture
Karpas [60] 2003 18 Two 24 120 42 Retrospective Yes NR
Kent [61] 2010 12 Two 26 60 38 Retrospective NR NR
Ketterl [13] 1988 161 Two 24 168 32 NA NA NA
Kim [63] 2011 130 Two 60 168 124.8 Retrospective Yes Laboratory, Culture
Klouche [22] 2012 84 Both 24 68 35 Prospective Yes Culture
Koo [62] 2001 22 Two 24 78 41 Prospective Yes Symptoms, Imaging, Laboratory
Lai [64] 1996 39 Two 30 84 48 Prospective Yes Symptoms, Laboratory
Lee [65] 2013 17 Two 24 96 48 Retrospective Yes Symptoms, Laboratory, Culture
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Table 1 General characteristics, record bias and reporting bias of included studies (Continued)
Leung [66] 2011 38 Two 24 123 58 Retrospective Yes Symptoms,Laboratory
Li [67] 2015 10 Both 78 187.2 103.2 Retrospective Yes Symptoms, Laboratory, Culture
Lieberman [68] 1994 32 Two 24 74 40 Retrospective NR NR
Macheras [69] 2012 35 Two 84 168 139.2 Retrospective Yes NR
Magnan [70] 2001 8 Two 24 48 35 Retrospective NR NR
Masri [71] 2007 29 Two 24 88 47 Retrospective Yes Symptoms, Laboratory
McDonald [72] 1989 81 Two 24 163.2 66 Prospective Yes Culture
McKenna [73] 2009 30 Two 24 60 35 Retrospective Yes Laboratory
Miley [74] 1982 46 Single 32 – 48.5 Prospective NR Unclear
Morales [75] 1999 37 Two 36 156 57.6 NA NA NA
Morscher [76] 1994 74 Both 12 132 84 NA Yes Symptoms, Imaging, Laboratory
Mulcahy [77] 1996 15 Single 24 84 53 Retrospective Yes Symptoms, Imaging, Laboratory, Culture
Nestor [78] 1994 34 Two 24 72 47 Retrospective Yes Culture
Neumann [79] 2011 44 Two 36 120 67 Retrospective Yes Laboratory
Nusem [80] 2006 18 Two 60 168 108 Retrospective Yes Unclear
Oussedik [9] 2010 50 Both 66 105.7 81.6 Prospective Yes Imaging, Laboratory
Pignatti [81] 2010 41 Two 60 120 63.6 Retrospective Yes Symptoms, Imaging, Laboratory
Raut [82] 1995 57 Single 24 151 88 Prospective Yes Symptoms, Laboratory
Romanò [83] 2012 183 Two 24 104 56 Retrospective Yes Laboratory, Culture
Rudelli [84] 2008 32 Single 24 96 52.8 Unclear Yes Imaging, Laboratory, Culture
Sabry [85] 2013 78 Two 24.3 135.3 58 Retrospective Yes Symptoms, Laboratory
Sanchez [86] 2009 168 Two 24 192 84 Retrospective Yes Symptoms, Culture
Sanzen [87] 1988 102 Both 24 108 – Prospective Yes Culture
Schneider [88] 1989 26 Single 12 108 – NA Yes NA
Schwarzkopf [89] 2014 56 Two 12 – 32.4 Retrospective Yes Laboratory, Culture
Seung-Jae [90] 2009 34 Two 24 120 52.8 Retrospective Yes Symptoms, Culture
Stockley [91] 2008 114 Two 24 175 74 Prospective Yes Symptoms, Laboratory, Culture
Sudo [25] 2008 7 Two 27.6 73.2 60 Retrospective Yes Symptoms, Imaging, Laboratory
Takigami [92] 2010 8 Two 24 81 49 Retrospective Yes Symptoms, Laboratory
Thabe [93] 2007 16 Two 72 120 75.6 Prospective Yes NR
Toulson [94] 2009 82 Two 24 203 64.8 Retrospective Yes Unclear
Ure [95] 1998 20 Single 42 205.2 118.8 Prospective Yes Symptoms, Imaging, Laboratory, Culture
van Diemen [96] 2013 136 Two 24 180 72 Retrospective Yes Symptoms, Imaging, Laboratory, Culture
Wang [97] 2011 12 Two 36 96 64.8 NA Yes NR
Weber [98] 1986 33 Both 60 96 72 Retrospective NR Laboratory
Whittaker [99] 2009 41 Two 25 83 49 Retrospective Yes Culture, Laboratory
Wilson [100] 1974 19 Single 24 – – Prospective Culture
Wilson [24] 1989 22 Both 36 120 60.2 Prospective Yes Symptoms, Imaging, Laboratory
Winkler [27] 2008 37 Single 63 183 103 Prospective Yes Symptoms, Imaging, Laboratory
Wolf [101] 2014 92 Both 24 – – Retrospective Yes Symptoms, Laboratory, Culture
Wroblewski [23] 1986 101 Single 38.8 – – Prospective NR NR
Yamamoto [102] 2003 17 Two 14 62 38 Retrospective Yes Laboratory
Yoo [103] 2009 12 Single 39.6 135.6 86.4 Prospective Yes Laboratory, Culture
Younger [104] 1997 48 Two 24 63 43 Prospective Yes Culture
Zeller [105] 2014 99 Single 24 – 41.6 Prospective Yes NA
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abstracts. Seventyfive studies reported on two-stage
exchanges (n = 3679), of which 68 were full texts and 7
abstracts. Characteristics of the included studies are
summarized in Table 1.
The number of patients undergoing a single-stage
exchange ranged from 12 to 583, with a follow-up of 12
to 183 months. Considering a single-stage exchange per-
formed with cementless implants (with or without
antibiotic-loaded bone grafts) we found a total of 148
patients (mean follow-up: 78.1 months) whereas for
single-stage exchange performed with cemented implant
involved 1271 patients (mean follow-up: 78.1 months).
The number of cases for only two-stage exchange studies
ranged from 7 to 186, with a follow-up of 12 to
203 months.
Quality assessment
The quality of included studies is shown in Table 1.
Overall, 62 % of included studies were retrospective,
29 % prospective and 8 % were not definable because
the full text was unavailable. Observational studies can
produce high quality information but, given the nature
of these study design, the lack of a control group and
the likely confounding variables, the methodological
Fig. 2 Proportional meta-analysis regarding infection recurrence after single-stage hip arthroplasty
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quality was limited leading to difficult generalisation of
results. The outcome was specified in the majority of the
studies (84 %), selecting infection recurrence as the
elective outcome to reflect the success of the two types
of interventions. In the half of the included studies, the
infection recurrence was diagnosed with more than two
measurements (i.e. positive culture, clinical symptoms,
imaging etc.). Nevertheless, a unique and universal def-
inition of ‘hip periprosthetic infection’ was not adopted
and among studies.
Concerning data reporting, only 57.3 % of the studies
gave a description of their criteria for selecting either a
single- or two-stage exchange arthroplasty. Other rele-
vant variables such as the indication for primary hip
arthroplasty or host type were poorly reported (49.0 %
and 36.5 % respectively). Other variables, such as age
(90.7 %), gender (86.4 %), isolated pathogen (91.6 %),
duration of interim period between stages (88.6 %), im-
plant type used at exchange arthroplasty (72 %), length
of antibiotic therapy (76.3 %), number of patients lost to
follow-up (73.8 %) were more often reported.
Recurrent infection
Single-stage vs two-stage
We have analysed the data using a random-effects model
to incorporate the wide range of variables.
The mean pooled proportion of recurrent infection
was 12 % (95 % CI = 8 %-17 %) in single-stage hip ex-
change (1608 cases, n = 31 studies) and demonstrated
high clinical and methodological inconsistency between
the studies included (I2 value = 80.3 %, p < 0.0001)
(Fig. 2).
The mean pooled proportion of recurrence of infec-
tion was 9 % (95 % CI = 8 %-11 %) in two-stage hip ex-
change (3679 cases, n = 74 studies) and demonstrated
moderate clinical and methodological inconsistency be-
tween the studies included (I2 value = 50.3 %, p < 0.0001)
(Fig. 3).
The combined overlapped CIs from single- and two-
stage exchanges suggests similar effect between the inter-
ventions, as represented in Fig. 4. This estimate was
confirmed by the comparisons of the available controlled
studies (n = 15): no statistically significant difference be-
tween people undertaking a single- versus a two-stage ex-
change in terms of recurrence of infection with a pooled
odds ratio of 1.37 (95 % CI = 0.68-2.74, I2 = 45.5 %, p =
0.03) (Fig. 5).
Single-stage cementless vs single-stage cemented
The mean pooled proportion of infection recurrence in
a single-stage hip cementless exchange (148 cases, n = 6
studies) was 14 % (95 % CI 4 %-28 %), whereas in a
cemented exchange (1271 cases, n = 19 studies) it was
12 % (95 % CI 7 %-17 %). In both analyses a high clinical
Fig. 3 Proportional meta-analysis regarding infection recurrence
after two-stage hip arthroplasty
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and methodological inconsistency was shown between
the included studies (I2 value = 77.4 % for cementless
and I2 value = 83.3 % for cemented; p < 0.0001).
Figures 6 and 7 present the pooled proportion for
cementless and cemented hip exchanges. The combined
overlapped 95 % CIs from cementless and cemented
single-stage exchanges suggests similar effect between
the interventions studied, as represented in Fig. 8.
Discussion
This systematic review analyses the current published
literature regarding a single- and two-staged exchange
for hip periprosthetic infections, where the number of
reported two-stage exchange arthroplasty studies largely
exceeds that of a single-stage ones.
This study includes a much higher number of studies
and patients compared to previous systematic reviews
comparing both treatment options in a more limited
population [14, 15] and is also, to our knowledge, the
first attempt to investigate separately cemented and
cementless one-stage revision procedures.
Our results failed to demonstrate a statistical difference
between a single- and two-stage exchange arthroplasty,
when applying a random effect model. Lange et al. [14]
identified only a limited superiority of two-stage exchange
arthroplasty in infection eradication, highlighting the low
quality of available material, while Beswisk et al. [15] could
not demonstrate any difference in eradication rates follow-
ing a systematic review of studies with a minimum of
24 months of follow-up.
In line with these findings, when considering compara-
tive studies only, the available material did not allow us
to prove the superiority of single- or two-stage exchange
arthroplasty, while a high heterogeneity of results was
Fig. 4 Combined overlapped CIs from single- and two-stage exchange proportional meta-analyses
Fig. 5 Meta-analysis regarding infection recurrence after single-stage versus two-stage–exchange
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observed. As an example, Klouche and co-workers
[22], recently reported no infection recurrence after
single-stage exchange arthroplasty, even without using
antibiotic-loaded cement, while Wolf et al. [23] dem-
onstrated a 43 % infection recurrence rate after single-
stage exchange, compared to only 4 % after two-stage
revision. Further analysing their data, these authors
provided evidence that the difference between the two
treatments could be due to the better results obtained
with a two-stage approach in more compromised
hosts, while either seem to perform equally well, when
normal hosts and early infections are involved [23].
Based upon the random-effects model used in our study,
the rate of infection recurrence following a single-stage
cementless exchange arthroplasty is not significantly differ-
ent from single-stage cemented exchange. Once again, the
limited number of studies and heterogeneity between both
types, cemented and cementless, are worth considering.
More generally, the following limitations of the present
study do apply. Patient selection and the eligibility for a
single- or two-stage exchange arthroplasty may differ across
centers; pathogen and host’s type, implant model and de-
gree of bone loss, type of hip spacer, use and dose of local
antibiotics, time interval between stages, post-operative sys-
temic antibiotic treatment, definition of infection, diagnosis
and surveillance protocols are all important variables [5, 11,
24–27] that were not reported uniformly across studies and
were not considered in the present analysis.
A further limitation of this review concerns the study
end-point, that we restricted to reporting infection
recurrence, which limits the ability to catch differences in
functional outcome, quality of life, or economical impact
related to a given surgical option. In addition, we paid at-
tention to the definition of measurements for recurrence
of infection in order to investigate the “outcome reporting
bias” but we were unable to distinguish between recurrent
and new infections, as such a distinction was not made in
the majority of the studies. The conventional definition of
a ‘new’ infection is the isolation of a new microorganism,
as opposed to the detection of the same pathogen in ‘re-
current’ infections, however we feel such a differentiation
is unreliable. The microbiological results following peri-
prosthetic samples are too unpredictable, especially after
previous antibiotic treatment. The criteria for differentiat-
ing between recurrent and new infections is weakly sup-
ported in the literature, and somewhat artificial [16].
Classifing the design of included studies in order to judge
their quality and internal validity was difficult. In fact, for
an important part of studies the design assigned was un-
clear, and considering the inclusion of a paper or abstract
published only in English we had an additional limit.
We found a substantial presence of the “record bias”
for the majority of studies. Out of the 90 studies in-
cluded, only 15 studies had a controlled group. The lack
of a control group, and the prospective collection of data
according to a protocol established before the beginning
of the study, can affect the methodological quality limit-
ing the external validity of findings.
We call for the need of large, multi-center randomised
controlled trials with higher quality assessment in order to
Fig. 6 Proportional meta-analysis regarding infection recurrence after cementless single-stage exchange
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establish the superiority of one type of surgical treatment
over another. However, certain circumstantial limitations
such as the low incidence of the disease, relatively small
patient cohorts, need for long-term follow-up, and varia-
tions in microorganisms and patients’ co-morbidities,
would also make a large controlled prospective study in
this field extremely challenging.
Conclusion
No superiority was seen for a two-stage exchange
arthroplasty over that of a single-stage for chronic
periprosthetic hip infections, nor a statistical differ-
ence between cemented and cementless single-stage
exchanges. This may reflect the shear complexity of
this patient cohort and the difficulty in finding the
true answer, and further reiterates that the ultimate
choice of treatment modality depends on a variety of
parameters not addressed in this review. This should
include the patient’s preoperative clinical status, po-
tential benefits in function and quality of life to be
gained from treatment, its economical implications,
and complication rates.
Fig. 7 Proportional meta-analysis regarding infection recurrence after cemented single-stage exchange
Fig. 8 Combined overlapped CIs from cementless and cemented single-stage exchange
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Appendix 1
Keywords entered either alone or in a variety of combi-
nations during the systematic review process.
Hip Infection
Arthroplasty Prosthesis
Total hip replacement THR
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